Maverick Capital Ltd. Purchases Shares of 425,125 Insmed, Inc. $INSM

Key Points

• Maverick Capital Ltd. has invested approximately $32.43 million in Insmed, acquiring 425,125 shares, representing about 0.23% of the company.
• Recent analyst reports indicate an optimistic outlook for Insmed, with price targets raised by firms like JPMorgan and Stifel Nicolaus, suggesting a "Moderate Buy" rating.
• Insiders, including CFO Sara Bonstein and CEO William Lewis, have sold significant stakes in the company, indicating a decrease in their ownership positions.

Maverick Capital Ltd. purchased a new stake in Insmed, Inc. (NASDAQ:INSM - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm purchased 425,125 shares of the biopharmaceutical company's stock, valued at approximately $32,433,000. Maverick Capital Ltd. owned approximately 0.23% of Insmed as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Insmed in the 1st quarter valued at about $88,351,000. Brown Advisory Inc. acquired a new stake in Insmed in the 4th quarter valued at about $45,773,000. Duquesne Family Office LLC grew its stake in Insmed by 2,867.4% in the 4th quarter. Duquesne Family Office LLC now owns 593,470 shares of the biopharmaceutical company's stock valued at $40,973,000 after acquiring an additional 573,470 shares during the last quarter. 1832 Asset Management L.P. acquired a new stake in Insmed in the 1st quarter valued at about $37,214,000. Finally, Wellington Management Group LLP grew its stake in Insmed by 62.5% in the 1st quarter. Wellington Management Group LLP now owns 1,222,627 shares of the biopharmaceutical company's stock valued at $93,274,000 after acquiring an additional 470,401 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Truist Financial raised their price target on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Bank of America raised their price target on shares of Insmed from $94.00 to $109.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. Leerink Partners raised their target price on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. Stifel Nicolaus raised their target price on shares of Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research report on Thursday, August 14th. Finally, Jefferies Financial Group raised their target price on shares of Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a research report on Wednesday, August 13th. Sixteen research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $134.79.

Insmed Stock Down 0.7%

NASDAQ:INSM traded down $0.97 during mid-day trading on Thursday, reaching $142.53. The stock had a trading volume of 2,012,737 shares, compared to its average volume of 2,805,286. The business's 50 day moving average is $112.91 and its 200 day moving average is $88.79. The stock has a market cap of $30.13 billion, a P/E ratio of -24.96 and a beta of 0.97. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $146.84.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same quarter in the previous year, the business earned ($1.94) earnings per share. Insmed's revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares in the company, valued at approximately $8,352,401.94. This represents a 52.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 129,805 shares of the business's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $100.39, for a total value of $13,031,123.95. Following the completion of the sale, the chief executive officer directly owned 233,924 shares of the company's stock, valued at approximately $23,483,630.36. This trade represents a 35.69% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 535,320 shares of company stock valued at $54,581,793. 3.00% of the stock is currently owned by company insiders.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.